Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (91-100 of 300) with videos related to

Pageof 30
Sort By:
Leukemia & Lymphoma|October 28, 2023
Understanding treatment decisions for Hodgkin lymphoma: a qualitative studyAnita J Kumar, Laurie K Pearson, John B Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
ASCO Living Guidelines: The Next FrontierVeda N Giri, Thomas K Oliver, R Bryan Rumble, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphomaJennifer R Brown, Heather Yeckes, Jonathan W Friedberg, et al.
Cancer|August 28, 2003
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicityJonathan W Friedberg, Donna Neuberg, Helen Kim, et al.
Annals of Internal Medicine|July 1, 2014
Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort studyJane C Weeks, Hajime Uno, Nathan Taback, et al.
Molecular Cancer Therapeutics|June 5, 2019
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>Girija Dasmahapatra, Dmitry Lembersky, Minkyeong P Son, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2016
Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin LymphomaPatrick M Reagan, Andrea Baran, Jennifer L Kelly, et al.
Molecular Cancer Therapeutics|July 14, 2011
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoGirija Dasmahapatra, Dmitry Lembersky, Minkyeong P Son, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736Deborah M Stephens, Hongli Li, Michael L LeBlanc, et al.
International Journal of Radiation Oncology, Biology, Physics|July 31, 2016
Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for RelapseSughosh Dhakal, James E Bates, Carla Casulo, et al.
Pageof 30

Showing results (91-100 of 300) with videos related to

Sort By:
Pageof 30
Leukemia & Lymphoma|October 28, 2023
Understanding treatment decisions for Hodgkin lymphoma: a qualitative studyAnita J Kumar, Laurie K Pearson, John B Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
ASCO Living Guidelines: The Next FrontierVeda N Giri, Thomas K Oliver, R Bryan Rumble, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphomaJennifer R Brown, Heather Yeckes, Jonathan W Friedberg, et al.
Cancer|August 28, 2003
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicityJonathan W Friedberg, Donna Neuberg, Helen Kim, et al.
Annals of Internal Medicine|July 1, 2014
Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort studyJane C Weeks, Hajime Uno, Nathan Taback, et al.
Molecular Cancer Therapeutics|June 5, 2019
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>Girija Dasmahapatra, Dmitry Lembersky, Minkyeong P Son, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2016
Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin LymphomaPatrick M Reagan, Andrea Baran, Jennifer L Kelly, et al.
Molecular Cancer Therapeutics|July 14, 2011
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoGirija Dasmahapatra, Dmitry Lembersky, Minkyeong P Son, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736Deborah M Stephens, Hongli Li, Michael L LeBlanc, et al.
International Journal of Radiation Oncology, Biology, Physics|July 31, 2016
Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for RelapseSughosh Dhakal, James E Bates, Carla Casulo, et al.
Pageof 30